Israeli pill shows promise for diabetes

TEL AVIV, Israel — Oramed Pharmaceuticals, the Israeli drugmaker seeking to develop the first oral pill for diabetes, said a trial on type 2 diabetes patients showed that the medicine has promising therapeutic potential.

The one-week study of 30 patients also met safety goals, the Jerusalem-based company said Thursday. Oramed plans to follow the mid-stage trial with another study later this year.

“The results we announced today give us confidence about the chances of success in a bigger trial going forward,” Chief Executive Officer Nadav Kidron said at a press conference Thursday at the Tel Aviv Stock Exchange. “We are also excited about the potential of this drug for type 1 diabetes.”

The results bring Oramed, whose stock has more than tripled in the past year, a step closer to doing something no company has ever done: develop oral insulin. The technology has eluded scientists for decades and Novo Nordisk, a Danish developer of diabetes products valued at about $104 billion, has yet to develop a pill to replace daily shots.

While Oramed is years away from a potential approval, it’s taking advantage of the growing attention to raise money. The company raised $16 million on Dec. 25, five days after it said it had successful results in an early-stage type 1 diabetes study. On Jan. 24, the company filed to raise as much as $100 million.

The market for drugs to treat diabetes is likely to grow to more than $58 billion in 2018 from $35 billion in 2012, Standard &Poor’s wrote in an October report.

Diabetes afflicted 371 million people and killed 4.8 million worldwide in 2012, according to the International Diabetes Federation. People with type 2 diabetes don’t produce enough insulin, a hormone that helps the body use or store blood sugar, or can’t use the insulin properly. The illness, the most common form of diabetes, often strikes people over the age of 40, and is tied to obesity and sedentary lifestyles.

The drugmaker’s Protein Oral Delivery, or POD, technology, is based on research by scientists at Jerusalem’s Hadassah Medical Center.

The Phase IIa trial detailed Thursday will be followed by a Phase IIb study.

More in Local News

Turkey talk: Kindergartners explain the Thanksgiving holiday

Our annual pilgrimage led us this year to Pathfinder Kindergarten Center in Everett.

Police locate suspect in Snohomish River after he fled

They used a thermal-imaging camera to locate the man in the water near Dagmars Marina.

Electrical fire on roof of Marysville school extinguished

There was no apparent structural damage to Cascade Elementary School.

As police closed in, 2 heavily armed pot-shop robbers fled

Cops surrounded the place in Mountlake Terrace. The suspects were tracked by dogs and apprehended nearby.

Hiker rescued on Boulder River trail after 15-foot fall

She was reported to have possible leg and rib fractures.

Alleged philanderer attacked with hammer near Everett

His girlfriend had accused him of cheating and allegedly called on another man to confront him.

State waging war with tenacious ivy, an invasive ‘bully’

The public is being asked to help with a study by collecting and sending in samples.

Front Porch

EVENTS Holiday lights parade in Monroe Monroe will host a Holiday Lights… Continue reading

Most Read